Boston goes exclusive on paclitaxel stent rights
This article was originally published in Clinica
Boston Scientific now holds the exclusive rights to technology it uses in its blockbuster Taxus Express2 drug-eluting stent. The new arrangement comes after Boston's one-time rival, Cook, decided to stop pursuing the lucrative but highly competitive coronary vascular stent market and sold back its co-exclusive rights to the licensor for $25m.
You may also be interested in...
GSK creates another partnership centered on its vaccine adjuvant technology, this time with China's Xiamen Innovax.
Lab testing for COVID-19 has risen to a new high of 314,000 tests per week in Germany, where the concerns are perhaps less about test availability than staff numbers to oversee the testing protocols.
A new European Commission guidance document explains the regulatory basics and much- altered emergency market entry criteria for new entrants to devices sector amid the COVID-19 crisis.